CAR T-cell Therapy Articles

CRISPR Builds More Powerful CAR T Cells
Michel Sadelain, MD, PhD, discusses CRISPR and its effect on CAR T cells.
Expert Discusses CAR T-Cell Advances in ALL
Stephan Grupp, MD, PhD, discusses the phase II ELIANA study results and the next steps with chimeric antigen receptor T-cell therapy in acute lymphoblastic leukemia.
Expert Discusses JCAR017 CAR T-Cell Therapy in Non-Hodgkin Lymphoma
Leo I. Gordon MD, discusses results from the TRANSCEND trial and the next steps with chimeric antigen receptor T-cell therapy in non-Hodgkin lymphoma.
Novel Study of Next-Generation BCMA-Targeted CAR-Modified T Cells for Multiple Myeloma Opens at MSK
Ola Landgren, MD, PhD, discusses a new clinical trial at Memorial Sloan Kettering examining a novel myeloma-directed CAR T-cell therapy developed by researchers at the cancer center.
Juno Accelerates Development of JCAR017, Halts JCAR015
Juno therapeutics has shifted its focus toward the development of JCAR017 for relapsed/refractory diffuse large B-cell lymphoma after a series of toxicity-related setbacks culminated in the need to halt the development of JCAR015.
Pivotal Year Looms for CAR T-Cell Therapies
Chimeric antigen receptor T-cell therapies have already produced clinical trial results that, even by the lofty standards set by emerging immunotherapies, have been stunning.
Treatment with axicabtagene ciloleucel demonstrated an objective response rate of 82% and a complete response rate of 54% for patients with aggressive non-Hodgkin lymphoma.
Nursing Coordination Invaluable to Successful Delivery of CAR T Therapy
Proper care coordination and patient education are essential to the success of delivering chimeric antigen receptor T-cell therapy, particularly in preparing patients for potential adverse events.
Top Centers Exploring JCAR017 for Non-Hodgkin Lymphoma
After demonstrating early success in acute lymphoblastic leukemia, CAR T-cell therapies are now expanding into all areas of hematologic malignancies, including non-Hodgkin lymphoma.
Ibrutinib Could Enhance CAR T-Cell Treatment Impact in CLL
Treatment with concurrent ibrutinib improves expansion of chimeric antigen receptor T-cells and could subsequently improve response in patients with chronic lymphocytic leukemia, according to a study presented during the 2017 ASH Annual Meeting.
Publication Bottom Border
Border Publication